EFFEXOR XR
Clinical safety rating: caution
Comprehensive clinical and safety monograph for EFFEXOR XR (EFFEXOR XR).
Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI). It potently inhibits the reuptake of serotonin and norepinephrine, and weakly inhibits dopamine reuptake. It has no significant affinity for muscarinic, histaminergic, or alpha1-adrenergic receptors.
| Metabolism | Venlafaxine is extensively metabolized in the liver via CYP2D6 to its active metabolite, O-desmethylvenlafaxine (ODV). Minor pathways include CYP3A4 and CYP2C19. ODV is further metabolized by conjugation and oxidative pathways. Both venlafaxine and ODV are eliminated primarily by renal excretion. |
| Excretion | Renal: approximately 87% as metabolites (including venlafaxine, O-desmethylvenlafaxine, and other minor metabolites) and ≤5% as unchanged drug. Biliary/fecal: minimal (about 2%). |
| Half-life | Venlafaxine: 3-7 hours (short, requires extended-release formulation for once-daily dosing); active metabolite O-desmethylvenlafaxine: 9-13 hours (contributes to overall clinical effect). Steady-state achieved within 3 days. |
| Protein binding | Venlafaxine: 27% bound to plasma proteins; O-desmethylvenlafaxine: 30% bound (primarily to albumin and α1-acid glycoprotein). |
| Volume of Distribution | Venlafaxine: 7.5 L/kg (high, indicating extensive tissue distribution). |
| Bioavailability | Oral (extended-release): approximately 45% (due to first-pass metabolism; absolute bioavailability of immediate-release is ~40-45%). |
| Onset of Action | Oral (extended-release): Clinical improvement in depressive symptoms may begin within 1-2 weeks, but full therapeutic response typically requires 4-8 weeks. |
| Duration of Action | Oral (extended-release): 24 hours (allows once-daily dosing due to extended-release formulation). Tapering is required to avoid withdrawal symptoms. |
75 mg orally once daily; may increase by 75 mg/day increments every 4-7 days to max 225 mg/day.
| Dosage form | CAPSULE, EXTENDED RELEASE |
| Renal impairment | GFR 10-29 mL/min: reduce dose by 25-50%; GFR <10 mL/min: reduce dose by 50% and administer every other day. |
| Liver impairment | Child-Pugh class A or B: reduce dose by 50%; Child-Pugh class C: avoid use or reduce dose by 75% with careful monitoring. |
| Pediatric use | Children 8-17 years: initial 37.5 mg orally once daily for first 4 weeks; then increase to 75 mg once daily based on response; max 225 mg/day. Weight-based: 1.25 mg/kg/day initial, titrate to 2.5 mg/kg/day. Limited data for <8 years. |
| Geriatric use | Initial dose 37.5 mg orally once daily; titrate slowly in 37.5 mg increments every 1-2 weeks; maximum 225 mg/day. Monitor for hyponatremia, QTc prolongation, and bleeding risk. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for EFFEXOR XR (EFFEXOR XR).
| Breastfeeding | Venlafaxine and its active metabolite O-desmethylvenlafaxine are excreted into breast milk; M/P ratio for venlafaxine is approximately 2.5-4.0. Estimated relative infant dose is 5-10% of maternal weight-adjusted dose. Adverse effects in breastfed infants are rare but may include irritability, poor feeding, and weight gain concerns. American Academy of Pediatrics considers venlafaxine compatible with breastfeeding with caution, especially in premature infants or those with impaired drug metabolism. |
| Teratogenic Risk | First trimester: Studies suggest a small increased risk of congenital cardiac malformations (primarily ventricular septal defects) with venlafaxine exposure, absolute risk ~2-3%. Second trimester: No specific major malformations reported, but risk of persistent pulmonary hypertension of the newborn (PPHN) may be increased (absolute risk <1%). Third trimester: Risk of neonatal adaptation syndrome (irritability, feeding difficulties, respiratory distress, jitteriness) in up to 30% of exposed neonates. Paroxetine is considered higher risk; venlafaxine is moderate risk. |
■ FDA Black Box Warning
EFFEXOR XR is not approved for use in pediatric patients. Antidepressants increased the risk of suicidal thinking and behavior (suicidality) in short-term studies in children and adolescents with major depressive disorder (MDD) and other psychiatric disorders. Pooled analyses of short-term placebo-controlled trials in children and adolescents with MDD, obsessive compulsive disorder (OCD), or other psychiatric disorders showed a greater risk of adverse events representing suicidal behavior or thinking (suicidality) during the first few months of treatment in those receiving antidepressants. The risk of suicidal thinking and behavior was increased in a pooled analysis of short-term placebo-controlled trials in children and adolescents with MDD and other psychiatric disorders. The risk of suicidality was not observed in adults aged 65 and older; it was observed in adults aged 18 to 24. Close supervision of patients starting therapy is required.
| Serious Effects |
["Concomitant use with MAOIs or within 14 days of discontinuing an MAOI (risk of serotonin syndrome).","Concomitant use with linezolid or intravenous methylene blue (also risk of serotonin syndrome).","Hypersensitivity to venlafaxine or any excipients in the formulation."]
| Precautions | ["Suicidality risk: monitor for worsening of depression, suicidal thoughts/behaviors, especially at initiation and dose changes.","Serotonin syndrome: risk with concomitant serotonergic drugs (e.g., SSRIs, SNRIs, triptans, MAOIs).","Hypertension: dose-dependent increase in blood pressure; monitor blood pressure regularly.","Activation of mania/hypomania: screen patients for bipolar disorder before treatment.","Seizures: use with caution in patients with seizure disorders.","Angle-closure glaucoma: may precipitate an acute attack in patients with anatomically narrow angles.","Hyponatremia: may occur, especially in elderly or volume-depleted patients.","Abnormal bleeding: risk of bleeding events, especially with NSAIDs, aspirin, or anticoagulants.","Discontinuation syndrome: gradual taper recommended to avoid withdrawal symptoms.","Sexual dysfunction: may cause decreased libido, erectile dysfunction, or delayed ejaculation."] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure (venlafaxine may increase BP), liver function tests, and renal function. In third trimester, monitor for signs of neonatal adaptation syndrome (e.g., respiratory distress, feeding intolerance, jitteriness) in the newborn. Consider fetal echocardiography if first-trimester exposure occurs. Monitor maternal weight gain and nutritional status. |
| Fertility Effects | Venlafaxine may cause sexual dysfunction (delayed ejaculation, anorgasmia, decreased libido) in both men and women, potentially affecting fertility. However, no direct evidence of reduced fertility in humans. Hypothalamic-pituitary axis modulation may impact menstrual cycle regularity and ovulation. Discontinuation should be considered if fertility issues arise, under physician guidance. |